SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, The Lancet, vol.393, issue.10166, pp.31-39, 2019. ,
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy, New England Journal of Medicine, vol.380, issue.24, pp.2295-2306, 2019. ,
CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med, vol.380, pp.2295-2306, 2019. ,
Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?, Expert Opinion on Pharmacotherapy, pp.1-3, 2020. ,
Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes, Diabetes Care, vol.41, issue.1, pp.11-13, 2017. ,
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.380, issue.4, pp.347-357, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02543624
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, New England Journal of Medicine, vol.373, issue.22, pp.2117-2128, 2015. ,
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction, Circulation, vol.139, issue.22, pp.2516-2527, 2019. ,
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial, Circulation, vol.139, issue.11, pp.1384-1395, 2019. ,
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus, Circulation, vol.139, issue.22, pp.2528-2536, 2019. ,
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial, European Heart Journal, vol.37, issue.19, pp.1526-1534, 2016. ,
The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure, Circulation, vol.136, issue.16, pp.1459-1461, 2017. ,
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, New England Journal of Medicine, vol.381, issue.21, pp.1995-2008, 2019. ,
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, New England Journal of Medicine, vol.383, issue.15, pp.1413-1424, 2020. ,
SGLT2 inhibitors in heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, pp.31824-31833, 2020. ,